News & analysis on the clinical development and manufacture of large molecule drugs
By Staff Reporter
- Last updated on
CEO Jean-François Mouney
French biopharma Genfit saw its shares surge 16% this week after Deutsche Bank analyst, Alethia Young, issued a positive note on the firm based on the potential of the “NASH” non-alcoholic steatohepatitis market.
Young set a €110 ($150) per share target for Genfit, citing an ongoing Ph IIb trial of its NASH candidate, GFT505, as an indication that concerns about potential safety problems related to its target – peroxisome proliferator-activated receptors (PPAR) – are unfounded.